

DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

7858 '01 AUG -3 P1:41

AUG - 2 2001

The Weinberg Group Inc.
Attention: Nicholas M. Fleischer, R.Ph., Ph.D.
1200 Nineteenth St. N.W., Suite 300
Washington, DC 20036-2400

Docket No. 01P-0109/CP1

Dear Dr. Fleischer:

This is in response to your petition filed on March 2, 2001, requesting permission to file an Abbreviated New Drug Application (ANDA) for the following drug product: Doxycycline (Monohydrate) Capsules USP, 75 mg. The reference listed drug product to which you refer in your petition is Monodox® [Doxycycline (Monohydrate)] Capsules USP, 100 mg, approved under NDA 50-641 held by Oclassen Pharmaceuticals, Inc. You also note that Monodox® [Doxycycline (Monohydrate)] Capsules are marketed in both 50 mg and 100 mg strengths.

Your request involves a change in strength from that of the reference listed drug product (i.e., from 100 mg to 75 mg). The change you request is the type of change that is authorized under the Act.

We have reviewed your petition under Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (Act) and have determined that it is approved. This letter represents the Agency's determination that an ANDA may be submitted for the above-referenced drug product.

Under Section 505(j)(2)(C)(i) of the Act, the Agency must approve a petition seeking a strength that differs from the strength of the listed drug product unless it finds that investigations must be conducted to show the safety and effectiveness of the differing strength.

The Agency finds that the change in strength for the specific proposed drug product does not pose questions of safety or effectiveness because the uses, dose, and route of administration of the proposed drug product are the same as that of the listed drug product. The Agency concludes, therefore, that investigations are not necessary in this instance. In addition, if shown to meet bioavailability requirements, the proposed drug product can be expected to have the same therapeutic effect as the listed reference drug product.

The approval of this petition to allow an ANDA to be submitted for the above-referenced drug product does not mean that the Agency has determined that an ANDA will be approved for the drug product. The determination of whether an ANDA will be approved is not made until the ANDA itself is submitted and reviewed by the Agency.

01P-0109

PAVI


01P-0109/CP1

To permit review of your ANDA submission, you must submit all information required under Sections 505(j)(2)(A) and (B) of the Act. To be approved, the drug product will, among other things, be required to meet current bioavailability requirements under Section 505(j)(2)(A)(iv) of the Act. We suggest that you submit your protocol to the Office of Generic Drugs, Division of Bioequivalence for this drug product prior to the submission of your ANDA. During the review of your application, the Agency may require the submission of additional information.

The listed drug product to which you refer in your ANDA must be the one upon which you based this petition. In addition, you should refer in your ANDA to the appropriate petition docket number cited above, and include a copy of this letter in the ANDA submission.

A copy of this letter approving your petition will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely yours,



Gary J. Buehler

Director

Office of Generic Drugs

Center for Drug Evaluation and Research